Xilio Therapeutics' CEO will speak at the TD Cowen Health Care Conference on March 3, 2025. Webcast available.
Quiver AI Summary
Xilio Therapeutics, Inc. has announced that CEO René Russo will take part in a fireside chat at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 9:50 am EST. The event will be available for live viewing through a webcast on the company's website, with a replay accessible for 30 days afterward. Xilio Therapeutics is focused on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects. Their proprietary platform supports a pipeline of innovative I-O molecules targeting the tumor microenvironment. For more information, the company invites visits to their website and LinkedIn page.
Potential Positives
- Participation of the CEO in a prominent health care conference enhances the company's visibility and credibility within the industry.
- The live webcast allows for greater investor engagement and provides an opportunity for real-time dissemination of information about the company's developments.
- The focus on tumor-activated immuno-oncology therapies positions Xilio Therapeutics strategically within a rapidly evolving and competitive biotech sector, potentially attracting investor interest.
- The company's proprietary platform and ongoing development of novel therapies highlight its commitment to innovation and improving cancer treatment outcomes.
Potential Negatives
- None
FAQ
What is Xilio Therapeutics known for?
Xilio Therapeutics is known for developing tumor-activated immuno-oncology therapies for cancer treatment.
When will the fireside chat take place?
The fireside chat will take place on Monday, March 3, 2025, at 9:50 am EST.
How can I access the live webcast?
The live webcast can be accessed in the “Events & Presentations” section of the Xilio Therapeutics website.
How long will the webcast be available after the event?
A replay of the webcast will be available for 30 days following the presentation.
How does Xilio Therapeutics aim to improve cancer treatment?
Xilio Therapeutics aims to improve cancer treatment by localizing anti-tumor activity within the tumor microenvironment to minimize side effects.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$XLO Insider Trading Activity
$XLO insiders have traded $XLO stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $XLO stock by insiders over the last 6 months:
- SCIENCES, INC. GILEAD purchased 1,759,978 shares for an estimated $1,830,377
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$XLO Hedge Fund Activity
We have seen 10 institutional investors add shares of $XLO stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY removed 520,743 shares (-34.2%) from their portfolio in Q4 2024, for an estimated $497,309
- UBS GROUP AG added 233,668 shares (+1485.2%) to their portfolio in Q4 2024, for an estimated $223,152
- BALYASNY ASSET MANAGEMENT L.P. added 70,744 shares (+26.0%) to their portfolio in Q4 2024, for an estimated $67,560
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 49,093 shares (+inf%) to their portfolio in Q4 2024, for an estimated $46,883
- TWO SIGMA SECURITIES, LLC removed 44,445 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $42,444
- APTUS CAPITAL ADVISORS, LLC added 41,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $39,155
- CITADEL ADVISORS LLC added 40,316 shares (+inf%) to their portfolio in Q4 2024, for an estimated $38,501
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50 am EST.
A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at
https://ir.xiliotx.com/
. A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting
www.xiliotx.com
and follow us on LinkedIn (Xilio Therapeutics, Inc.).
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Investor and Media Contact
Scott Young
Vice President, Investor Relations and Corporate Communications
investors@xiliotx.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
